Oncoinvent ASA (OSL:ONCIN)
Norway
· Delayed Price · Currency is NOK 49.10
-0.30 (-0.61%)
Apr 29, 2026, 9:37 AM CET
Oncoinvent ASA Company Description
Oncoinvent ASA, a clinical stage company, develops radiopharmaceutical therapies against cancer.
Its lead product candidate is Radspherin, an alpha-radiation therapy candidate for treating cancer that have spread to body cavities, including peritoneum in two phase 1/2a trials and one randomized phase 2 trial.
The company is based in Oslo, Norway.
Oncoinvent ASA
| Country | Norway |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 36 |
| CEO | Oystein Soug |
Contact Details
Address: Gullhaugveien 7 Oslo, 0484 Norway | |
| Phone | 47 22 18 33 05 |
| Website | oncoinvent.com |
Stock Details
| Ticker Symbol | ONCIN |
| Exchange | Oslo Børs |
| Fiscal Year | January - December |
| Reporting Currency | NOK |
| ISIN Number | NO0013251173 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Oystein Soug M.Sc | Chief Executive Officer |
| Gro Elisabeth Hjellum | Chief Operating Officer |
| Kristine Lofthus | Chief Production Officer |
| Stian Brekke | Head of Regulatory Affairs |
| Dr. Kari Myren M.D. | Chief Medical Officer |
| Anne Cecile Alvik | Head of Quality Assurance and Employee Representative Director |
| Dr. Anne-Kirsti Aksnes Ph.D. | Chief Clinical Officer |
| Dr. Ramzi Amri M.D., Ph.D. | Chief Financial Officer |
| Kaja Tunhovd Johansen | Head of Quality Control |